Douglas Lane & Associates LLC Has $50.16 Million Stock Holdings in Elanco Animal Health Incorporated $ELAN

Douglas Lane & Associates LLC cut its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 9.8% during the second quarter, Holdings Channel reports. The firm owned 3,512,675 shares of the company’s stock after selling 382,515 shares during the quarter. Douglas Lane & Associates LLC’s holdings in Elanco Animal Health were worth $50,161,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Dimensional Fund Advisors LP raised its position in shares of Elanco Animal Health by 14.3% during the first quarter. Dimensional Fund Advisors LP now owns 20,464,727 shares of the company’s stock worth $214,875,000 after purchasing an additional 2,563,740 shares during the period. T. Rowe Price Investment Management Inc. raised its position in shares of Elanco Animal Health by 1.9% during the first quarter. T. Rowe Price Investment Management Inc. now owns 15,983,391 shares of the company’s stock worth $167,826,000 after purchasing an additional 292,655 shares during the period. Nuveen LLC acquired a new stake in shares of Elanco Animal Health during the first quarter worth $115,212,000. Goldman Sachs Group Inc. raised its position in shares of Elanco Animal Health by 104.5% during the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock worth $50,268,000 after purchasing an additional 2,445,872 shares during the period. Finally, Private Management Group Inc. raised its position in shares of Elanco Animal Health by 10.9% during the first quarter. Private Management Group Inc. now owns 2,614,921 shares of the company’s stock worth $27,457,000 after purchasing an additional 257,779 shares during the period. 97.48% of the stock is owned by institutional investors and hedge funds.

Elanco Animal Health Stock Performance

Shares of ELAN stock opened at $18.52 on Friday. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.60 and a quick ratio of 1.40. Elanco Animal Health Incorporated has a fifty-two week low of $8.02 and a fifty-two week high of $19.08. The stock’s 50-day moving average is $16.37 and its two-hundred day moving average is $13.20. The firm has a market cap of $9.20 billion, a P/E ratio of 21.53, a PEG ratio of 3.49 and a beta of 1.62.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Thursday, August 7th. The company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.06. Elanco Animal Health had a return on equity of 7.04% and a net margin of 9.68%.The company had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.19 billion. During the same period in the prior year, the firm posted $0.30 EPS. The business’s revenue was up 4.8% compared to the same quarter last year. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. Analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ELAN. Leerink Partnrs raised Elanco Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 17th. Leerink Partners raised Elanco Animal Health from a “market perform” rating to an “outperform” rating and set a $18.00 price objective for the company in a research note on Thursday, July 17th. UBS Group increased their price objective on Elanco Animal Health from $18.00 to $19.00 and gave the stock a “buy” rating in a research note on Friday, August 8th. Piper Sandler increased their price objective on Elanco Animal Health from $12.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, August 11th. Finally, Wall Street Zen raised Elanco Animal Health from a “hold” rating to a “buy” rating in a research note on Saturday, July 5th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $17.33.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.